Lamy Patrick's most recent trade in Akero Therapeutics Inc was a trade of 2,000 Common Stock done at an average price of $52.9 . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 52.88 per share. | 01 Jul 2025 | 2,000 | 29,891 (0%) | 0% | 52.9 | 105,760 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Grant, award, or other acquisition of securities at price $ 23.87 per share. | 30 Jun 2025 | 193 | 31,891 (0%) | 0% | 23.9 | 4,607 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 54.59 per share. | 20 Jun 2025 | 875 | 31,698 (0%) | 0% | 54.6 | 47,766 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 2,000 | 64,182 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 16 Jun 2025 | 2,000 | 34,573 (0%) | 0% | 19.9 | 39,740 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 53.82 per share. | 16 Jun 2025 | 1,500 | 33,073 (0%) | 0% | 53.8 | 80,726 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 55.09 per share. | 16 Jun 2025 | 500 | 32,573 (0%) | 0% | 55.1 | 27,546 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 54.00 per share. | 10 Jun 2025 | 919 | 32,573 (0%) | 0% | 54.0 | 49,625 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 4,000 | 66,182 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 02 Jun 2025 | 4,000 | 37,492 (0%) | 0% | 19.9 | 79,480 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 50.46 per share. | 02 Jun 2025 | 3,300 | 33,592 (0%) | 0% | 50.5 | 166,515 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 49.40 per share. | 02 Jun 2025 | 600 | 36,892 (0%) | 0% | 49.4 | 29,639 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 51.04 per share. | 02 Jun 2025 | 100 | 33,492 (0%) | 0% | 51.0 | 5,104 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 22 May 2025 | 4,000 | 33,492 (0%) | 0% | 50 | 200,000 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.37 per share. | 22 May 2025 | 4,000 | 37,492 (0%) | 0% | 44.4 | 177,480 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2025 | 4,000 | 84,904 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 8,000 | 70,182 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 07 May 2025 | 8,000 | 41,492 (0%) | 0% | 19.9 | 158,960 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 42.31 per share. | 07 May 2025 | 4,701 | 36,791 (0%) | 0% | 42.3 | 198,895 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 42.76 per share. | 07 May 2025 | 3,299 | 33,492 (0%) | 0% | 42.8 | 141,055 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 03 Mar 2025 | 1,000 | 34,492 (0%) | 0% | 19.9 | 19,870 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 1,000 | 78,182 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 48.09 per share. | 03 Mar 2025 | 1,000 | 33,492 (0%) | 0% | 48.1 | 48,090 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 57.03 per share. | 31 Dec 2024 | 5,000 | 33,492 (0%) | 0% | 57.0 | 285,150 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 31 Dec 2024 | 4,000 | 38,492 (0%) | 0% | 19.9 | 79,480 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 4,000 | 79,182 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Grant, award, or other acquisition of securities at price $ 19.69 per share. | 31 Dec 2024 | 234 | 34,492 (0%) | 0% | 19.7 | 4,607 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 52,100 | 52,100 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Lamy Patrick | Senior VP, Commercial Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 17,400 | 35,258 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 29.13 per share. | 16 Dec 2024 | 1,000 | 34,258 (0%) | 0% | 29.1 | 29,130 | Common Stock |
| Akero Therapeutics Inc | Lamy Patrick | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 30.79 per share. | 10 Dec 2024 | 925 | 17,858 (0%) | 0% | 30.8 | 28,481 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Grant, award, or other acquisition of securities at price $ 19.94 per share. | 28 Jun 2024 | 221 | 18,783 (0%) | 0% | 19.9 | 4,407 | Common Stock |
| Akero Therapeutics Inc | Patrick Lamy | Senior VP, Commercial Strategy | Sale of securities on an exchange or to another person at price $ 22.64 per share. | 11 Jun 2024 | 569 | 18,562 (0%) | 0% | 22.6 | 12,883 | Common Stock |
| Akero Therapeutics Inc | Lamy Patrick | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 83,564 | 83,564 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Patrick Lamy | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 18,570 | 18,570 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Patrick Lamy | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |